RAISE(ing) Support for Caregivers: State and National Resources for Family Care Partners
Dementia caregiving is a multifaceted domain, deeply influenced by research, strategy and personal experiences. How are these elements shaping the current and future landscape of care? Dr. Beth Fields...
10 Loka 202328min
Mental Health and Memory: The Connections between Chronic Mental Illness and Dementia
Like cognition, mental health is a key component of the brain — and overall — health. In what ways can mental health and chronic mental illness impact a person’s cognition and risk for dementia? Dr. A...
19 Syys 202340min
Highlights from the 2023 Alzheimer’s Association International Conference
The 2023 Alzheimer's Association International Conference (AAIC) in Amsterdam brought together the world's leading scientists, clinical researchers, early career investigators, caregiving researchers ...
5 Syys 202321min
A Fair Fight Against Alzheimer’s: The Need for Equity in Dementia Research and Care
How can we ensure that all communities are represented in Alzheimer’s and related dementias research and have access to the latest treatments and interventions? Dr. Carl Hill, the chief diversity, equ...
23 Elo 202332min
Agitation and Alzheimer’s: Strategies for Managing Behavioral and Psychological Symptoms of Dementia
Many people living with dementia experience behavioral symptoms alongside changes in their cognition. What can care partners and healthcare providers do to manage these behavioral changes? After leadi...
8 Elo 202340min
Promises to Practice: Creating Sustainable Community Partnerships to Support Alzheimer’s Research
Gina Green-Harris joins the podcast to discuss the importance of collaborating with communities in Alzheimer’s research. Sharing her experience as a researcher with the Wisconsin Alzheimer’s Institute...
26 Heinä 202345min
Study Shows APOE Gene Affects Hispanic Populations’ Risk of Cognitive Decline Differently to Non-Hispanic Populations
The APOE gene is recognized as a significant genetic risk factor for cognitive decline, with different alleles, like APOE e2, being seen as protective against decline and others, like APOE e4, indicat...
12 Heinä 202322min
Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment
On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the diseas...
7 Heinä 202333min
